Fast-read summaries of the latest findings, clinical updates, and research notes — curated from the frontlines of oncology science.
A 2026 Oncology Reports study shows mebendazole enhances chemotherapy and promotes macrophage polarization from M2 to M1 in patient tumor models and a mouse colon cancer model.
A 2026 Scientific Reports study demonstrates that a microbial levan enhances hepatic retention and antitumor activity of a PEGylated benzimidazole-curcumin nanocomplex in experimental liver cancer.
A 2026 Frontiers in Oncology case report documents a patient with metastatic HR+ breast cancer who achieved near-complete response using metabolic therapy combined with repurposed drugs.
Mebendazole inhibits PELI3 E3 ubiquitin ligase expression in HCC827 and A549 non-small cell lung cancer cells, increasing TRADD protein levels and restoring proapoptotic autophagy.
A new 2026 review in Pharmaceutics proposes curcumin as a molecular synergy amplifier whose clinical utility depends on mechanistic complementarity and pharmacokinetic synchronization with co-administered therapies.
Mebendazole shows modest single-agent cytotoxicity in patient-derived AML, ovarian, colorectal and renal cancer cells, but enhances irinotecan and cisplatin effects. In a mouse CT26 colon cancer model, mebendazole promotes M2→M1 macrophage polarization.
A 2026 review in Molecular Biology Reports summarizes preclinical evidence that monensin, a veterinary ionophore, demonstrates antitumor activity across breast, prostate, pancreatic, ovarian, renal, liver, thyroid, and brain malignancies.
A 2026 case report in Cureus documents severe drug-induced liver injury in a 65-year-old prostate cancer patient who self-administered veterinary fenbendazole and ivermectin for three months.
A July 2026 study in Apoptosis demonstrates that artemisinin-loaded liposomes suppress breast cancer metastasis and induce apoptosis by modulating the TIGIT/CD155 immune checkpoint axis in 4T1 cell and mouse models.
A 2026 study combines network pharmacology, molecular dynamics, and in vitro experiments to explore how curcumin targets gastric cancer pathways.
A 2026 systematic review evaluates mebendazole's preclinical and clinical evidence across glioblastoma, medulloblastoma, and meningioma, highlighting translational gaps.
A 2026 conceptual review highlights monepantel's emerging anticancer mechanisms, including mTOR inhibition and autophagy induction, based on preclinical evidence.
A novel methylene blue derivative, 1,9-dimethyl methylene blue, shows promise as a photosensitizer for photodynamic therapy against oropharyngeal cancer.
A synthetic curcumin analog called E145 shows potent anticancer activity by blocking NF-κB signaling in breast cancer cells and reducing lung metastasis in mice.
Curcumin suppresses NLRP3 inflammasome activation in tumor-associated macrophages, reducing inflammatory signals that drive breast cancer progression.
A 2026 preclinical study shows nitazoxanide, an FDA-approved antiparasitic drug, triggers ferroptosis in TNBC cells by disrupting iron homeostasis and degrading the beta-catenin/GPX4 axis. The findings are based on in vitro and zebrafish xenograft data only.
A 2026 preclinical study found that the synthetic curcumin analogue B-155 demonstrates significantly greater cytotoxicity than natural curcumin in SKOV3 ovarian cancer cells, with effects including G2/M cell-cycle arrest, apoptosis, and p38 MAPK binding. The study is limited to in vitro data.
In a 2026 preclinical study using patient-derived 3D spheroids, mebendazole prevented cellular invasion in 89% of meningioma samples by disrupting Rho-GTPase-mediated microtubule function. This is early laboratory evidence, not a clinical trial.
A 2026 preclinical study in the International Journal of Pharmaceutics developed a curcumin-releasing hydrogel that, when applied after prostate cancer surgery, suppressed tumor regrowth and reduced lymph node metastasis by maintaining high local drug concentration. Animal-model evidence only.
A 2026 preclinical study shows mebendazole impairs nucleotide metabolism enzymes in gastric cancer cells, causing cell cycle arrest and antiproliferative activity comparable to 5-FU with lower toxicity to normal cells. Laboratory evidence only.
A 2026 preclinical study shows curcumin induces ferroptosis in papillary thyroid cancer cells by downregulating GPX4, suppressing tumour growth in mice without organ toxicity.
A July 2026 review evaluates repurposed drugs — including ivermectin and artesunate — against renal cell carcinoma, identifying multiple targetable signalling pathways in preclinical models.
A 2026 case series in Integrative Medicine describes 6 stage IV cancer patients who showed prolonged survival after AMA-guided antiparasitic protocols including ivermectin and mebendazole.
Researchers at Chulalongkorn University found that ivermectin significantly suppressed estrogen-induced proliferation and downregulated ER, HER2, and TGF-β pathway markers in endocrine-resistant breast cancer cells, suggesting potential as a repurposed agent to overcome hormonal therapy resistance.
Researchers found that mebendazole at 0.7 µM reprogrammed oncogenic and tumor-suppressor networks across eight cancer cell lines, suppressing ENOX2 and MMP2 while activating RASSF1A by over 200-fold.
Chinese researchers found that combining ivermectin with metformin significantly inhibited MCF-7 breast cancer cell viability, migration, and invasion by suppressing PI3K/AKT/mTOR signaling and triggering autophagy.
A June 2026 study in Advanced Science describes a nanoplatform combining fenbendazole with photothermal therapy to trigger ferroptosis and dual immunotherapy in orthotopic bladder cancer mouse models.
A June 2026 study in Cell Reports Medicine found that a ketogenic diet acts as a metabolic vehicle that enhances mebendazole's anti-tumor effects in juvenile mouse models of high-grade glioma, allowing lower drug doses and improved survival.
Anticancer Research flagged the widely-shared Hulscher et al. study (84.4% clinical benefit) with a formal Expression of Concern: no control group, self-reported outcomes. The paper has not been retracted as of August 2026.
A June 2026 preclinical study from Rome found mebendazole significantly inhibited cell growth and migration in two pediatric low-grade glioma cell lines, supporting its potential as a repositioned therapeutic drug.
A 2026 ASCO abstract documents 182 self-reported fenbendazole users at MD Anderson out of 297,223 visits — with 138 different dosing schedules. A prevalence snapshot with major implications for research design.
A June 2026 South Korean study found ivermectin suppressed gastric cancer growth in patient-derived 3D organoids, achieving 82.48% cell death when combined with cisplatin — a more realistic tumor model than standard cell lines.
A July 2026 study from Wrocław found curcumin cut ATP in fibrosarcoma cells by up to 92% and drove 75% into permanent senescence — outperforming four other natural compounds with the best safety profile.
A June 2026 study from Bulgarian research institutions developed PEG-b-PCL polymer micelles to encapsulate fenbendazole, improving its delivery to triple-negative breast cancer cells — a promising nanoformulation approach at the preclinical stage.
In May 2026, the American Society of Clinical Oncology issued a formal clinical notice recommending against the use of fenbendazole and ivermectin as cancer treatments. We break down what the notice says — and what the emerging observational data shows.
A July 2026 study from Charles University found that flubendazole combined with temozolomide reduced glioblastoma cell proliferation and activated apoptosis pathways in three GBM cell lines. Preclinical data only.
Native curcumin has less than 1% oral bioavailability. A 2025–2026 wave of nanocarrier research (PLGA, liposomes, nanomicelles, stimuli-responsive particles) has achieved up to 178× improvement in plasma AUC. Two nanoformulations — Sinacurcumin and Lipocur — are now in Phase I/II cancer trials.
A June 2026 study from UC San Diego found ivermectin combined with recombinant methioninase outperformed four of five first-line chemotherapy drugs against colon cancer cells in vitro, with a chemosensitivity index of 6.7.
A 2026 review from Hamad Medical Corporation and Qatar University synthesizes the anticancer evidence for seven antiparasitic drugs — ivermectin, mebendazole, niclosamide, albendazole, artesunate, flubendazole, and pyrvinium pamoate — across multiple cancer types.
2025–2026 research confirms methylene blue as a mitochondrial electron shuttle that bypasses Complex I dysfunction, reduces ROS by 55–65%, inhibits tau aggregation, reduces senescent cells by ~28%, and shows early signal in treatment-resistant depression. Phase 3 Alzheimer's results remain mixed.
A prospective observational study of 197 cancer patients published in Anticancer Research (2026) found an 84.4% clinical benefit ratio with a compounded ivermectin + mebendazole regimen. Here is a detailed breakdown of the findings.
A 2026 study in Scientific Reports identified a specific epigenetic mechanism by which curcumin suppresses oral squamous cell carcinoma (OSCC): by downregulating the histone acetyltransferase EP300, curcumin blocks the Warburg effect in oral cancer cells.
2026 reviews and preclinical studies continue to explore methylene blue's dual role as a photodynamic therapy (PDT) sensitizer and metabolic disruptor in cancer cells. Here is a research summary.
In February 2026, the National Cancer Institute announced it had begun preclinical laboratory studies to evaluate ivermectin's potential anticancer properties. This is a significant signal from the world's largest cancer research institution.
Mebendazole crosses the blood-brain barrier — a rare pharmacokinetic advantage for brain tumor drugs. A Johns Hopkins Phase 1 trial confirmed safety at high doses combined with temozolomide. A 2025 study combined MBZ with bumetanide for a dual cytotoxic and anti-invasive effect in glioblastoma.
A 2025 study in Frontiers in Pharmacology traced a precise mechanism: fenbendazole suppresses HK2, triggering caspase-3/GSDME signaling to cause immunogenic pyroptosis in breast cancer cells. Tumor inhibition comparable to cisplatin in mouse xenograft models. Full mechanistic breakdown inside.
